



April 29, 2013

Integra LifeSciences Debuts Next-Generation Camino(R) Platform at 2013 American Association of Neurological Surgeons Annual Meeting

PLAINSBORO, N.J., April 29, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the debut of the next generation of the Camino® platform, an advanced monitoring system for continuous intracranial pressure (ICP) monitoring and cerebral spinal fluid (CSF) drainage. Integra is a leading provider of advanced ICP monitoring systems. Over 800 centers in the United States use the Camino platform for conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and stroke.

The new Camino platform includes the Integra® Camino® Intracranial Pressure (ICP) and Temperature Monitor and Integra® Camino® Flex Ventricular Catheter. Both products have received 510(k) Clearance from the United States Food and Drug Administration (FDA), and will be featured at the 2013 American Association of Neurological Surgeons Annual Meeting, April 27-May 1, 2013, in New Orleans, L.A.

"We are very pleased to introduce our next-generation Camino platform. For the first time, we are simultaneously debuting our market-leading Camino Monitor and a tunneled advanced monitoring catheter, making it easier for surgeons to take advantage of our newest technology," said Peter Ligotti, Integra's Vice President of Marketing, Neurosurgery. "Our Camino monitor has been completely updated and modernized, making it easier to use. It also offers our customers convenient options for utilizing both our current Camino fiber optic catheter technology, as well as the newest addition to the family, the Camino ventricular catheter, which utilizes strain gauge technology."

The Camino ICP Monitor is a modernized platform designed to incorporate both tunneled and bolted advanced monitoring technologies, which monitor ICP in either the parenchyma or ventricle space. Easily portable and ergonomically designed, the monitor integrates strain gauge and fiber optic monitoring technologies. It features up to five days of patient ICP data trending, and has a unique, large and highly visible touchscreen interface.

When coupled with the new Camino Monitor, the new Integra Camino Flex Ventricular Catheter provides clinicians access to a truly advanced system for the diagnosis and treatment of compromised neurological conditions. Unlike other tunneled ventricular catheters that depend upon CSF flow to measure ICP, Integra's Camino Flex Ventricular Catheter continuously monitors ICP independently in the ventricles, even when CSF flow cannot be established. A multilumen design also allows for simultaneous CSF drainage and ICP monitoring, providing uninterrupted measurement of patient pressure.

Integra, a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care, delivers a full line of neurocritical care solutions with its portfolio of cranial access kits, CSF drainage systems, including the AccuDrain® External CSF Drainage System and LimiTorr™ Volume Limiting CSF Drainage System, and the Licox® Brain Tissue Oxygen Monitoring platform.

[Integra LifeSciences](http://www.integralife.com), a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Gianna Sabella

Director, Corporate Communications

609-936-2389

Gianna.sabella@integralife.com